Capstan Therapeutics Stock

capstantx.comHealthcare / Healthcare providers & servicesFounded: 2021Funding to Date: $340MM

Capstan Therapeutics is a biotechnology company that strives to develop new treatments for a variety of diseases using in vivo cell engineering, which is a method that aims to modify cells inside the body. Their core technology involves targeted lipid nanoparticles (tLNPs) seeking to manipulate cells for therapeutic purposes. Areas of interest for the company include oncology, fibrosis, inflammatory disease, and blood disorders. Capstan Therapeutics was founded in 2021 and is headquartered in San Diego, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Capstan Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Capstan Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Capstan Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Justin Thacker
Chief Financial Officer
Priya Karmali Ph.D
Chief Technology Officer
Adrian Bot Ph.D
Founding Chief Scientific Officer & Executive Vice President of Research & Development
Haig Aghajanian Ph.D
Co-Founder & Vice President of Research
Laura Shawver Ph.D
President & Chief Executive Officer
Christian Homsy MD
Co-Founder
Ramin Farzaneh-Far MD
Chief Medical Officer

Board Members

Andrew Levin Ph.D
RA Capital Management
Erez Chimovits
OrbiMed
Fabio Pucci Ph.D
Leaps by Bayer
Michael Baran Ph.D
Pfizer Ventures
Michal Silverberg
Novartis Venture Fund
Nandita Shangari Ph.D
Novartis Venture Fund
Rajul Jain MD
Vida Ventures

Frequently Asked Questions About Capstan Therapeutics’ Stock

plusminus
Can you buy Capstan Therapeutics’ stock?
Capstan Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Capstan Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Capstan Therapeutics’ stock?
Yes, you can sell stock of a private company like Capstan Therapeutics. Forge can help you sell your Capstan Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Capstan Therapeutics’ stock price?
Capstan Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Capstan Therapeutics’ private market stock price with Forge Data.
plusminus
What is Capstan Therapeutics’ stock ticker symbol?
Capstan Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing
In a funding round led by investors such as Johnson & Johnson Innovation and Forbion, Capstan Therapeutics raised $175 million.
Updated on: Apr 19, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.